Filter Results:
(274)
Show Results For
- All HBS Web
(389)
- News (70)
- Research (274)
- Events (7)
- Multimedia (1)
- Faculty Publications (135)
Show Results For
- All HBS Web
(389)
- News (70)
- Research (274)
- Events (7)
- Multimedia (1)
- Faculty Publications (135)
Sort by
- 20 Aug 2007
- Research & Ideas
HBS Cases: Using Investor Relations Proactively
How should a company deliver financial news—both good and bad—to a broad spectrum of stakeholders, including investors, customers, government, and environmentalists? Energy giants Total and BP have learned best practices through trial and... View Details
- 01 Aug 2017
- First Look
First Look at New Research and Ideas, August 1
Abstract—Objective: Assess whether a commitment contract informed by behavioral economics leads to persistent virologic suppression among HIV-positive patients with poor antiretroviral therapy (ART) adherence. Design: Single-center pilot View Details
Keywords: Sean Silverthorne
- February 2013
- Article
An Activity-Generating Theory of Regulation
By: Joshua Schwartzstein and Andrei Shleifer
We propose an activity-generating theory of regulation. When courts make errors, tort litigation becomes unpredictable and as such imposes risk on firms, thereby discouraging entry, innovation, and other socially desirable activity. When social returns to activity are... View Details
Keywords: Courts and Trials; Lawsuits and Litigation; Governing Rules, Regulations, and Reforms; Theory
Schwartzstein, Joshua, and Andrei Shleifer. "An Activity-Generating Theory of Regulation." Journal of Law & Economics 56, no. 1 (February 2013): 1–38. (Lead Article.)
- 21 Feb 2017
- First Look
First Look at New Research: February 21
internal beneficiary that made connectedness salient yielded a persistent increase in productivity relative to a control group. We validate this effect in the laboratory and provide evidence that the effect is mediated by an enhanced... View Details
Keywords: Carmen Nobel
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
Keywords: Health Testing and Trials; Governing Rules, Regulations, and Reforms; Valuation; Product Development; Pharmaceutical Industry
Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023. (Revised July 2024.)
- 21 Jul 2006
- Op-Ed
Enron Jury Sent the Right Message
The most noteworthy message of the Enron trial is that corporate executives can be convicted in a court of law for a pattern of deception that may or may not be illegal. Left unaddressed in the trial were... View Details
Keywords: by Malcolm S. Salter
- 30 Dec 2013
- Research & Ideas
Most Popular Articles of 2013
alleviate congestion, and can actually increase it. Research by Jillian Berry Jaeker, Anita L. Tucker, and Michael H. Lee. Applying Random Coefficient Models to Strategy Research: Testing For Firm Heterogeneity, Predicting Firm-Specific... View Details
Keywords: by Staff
- 14 Dec 2020
- Research & Ideas
What Does December's Drug-Approval Dash Mean for COVID-19 Vaccines?
aspects of the drug trial and approval process, including allowing time for potential issues to materialize. When you see an FDA emergency approval for a COVID-19 vaccine, don't interpret this as a normal “FDA approval.” I understand that... View Details
- 09 Dec 2014
- First Look
First Look: December 9
experiment and their interactions can make it difficult to determine cause-and-effect relationships. Choosing the right sample size is important. How can we ensure reliable results? Randomized field trials, "blind" tests, and... View Details
Keywords: Sean Silverthorne
- 03 Nov 2015
- First Look
November 3, 2015
at facilitating communication and collaboration between practitioners and academics by introducing key vocabulary and concepts used in rigorous impact evaluation methods, starting with randomized controlled... View Details
Keywords: Sean Silverthorne
- 30 Jan 2012
- Research & Ideas
Measuring the Efficacy of the World’s Managers
larger number of organizations. The researchers have also started to work on management experiments, modeled on the randomized control trials adopted in the medical field. This... View Details
Keywords: by Carmen Nobel
- 02 Jun 2011
- Research & Ideas
Signing at the Top: The Key to Preventing Tax Fraud?
end of the tax form, after the form has been filled out and, consequently, after the potential cheating has occurred. (It's analogous to a witness first testifying in a court trial and then swearing on a Bible, "For the last twenty... View Details
- December 2006 (Revised August 2008)
- Case
Pervasis Therapeutics, Inc.
By: Robert F. Higgins and Virginia Fuller
In May 2005, Steve Bollinger was about to become president and chief operating officer of Pervasis Therapeutics, a small cell therapy start-up in Cambridge, Mass. If proven successful, Pervasis' product, Vascugel, could change the way vascular disease is treated and... View Details
Keywords: Business Startups; Venture Capital; Financial Strategy; Governing Rules, Regulations, and Reforms; Health Care and Treatment; Health Testing and Trials; Health Industry; Cambridge
Higgins, Robert F., and Virginia Fuller. "Pervasis Therapeutics, Inc." Harvard Business School Case 807-026, December 2006. (Revised August 2008.)
- 21 Aug 2012
- Research & Ideas
How to Sink a Startup
Tim Westergren of Pandora and Evan Williams of Twitter. YouTube cofounder and former CEO Chad Hurley has called the book "an invaluable alternative to real-world trial and error." A past recipient of the HBS student-voted award for... View Details
Keywords: by Garry Emmons
- 2010
- Chapter
From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance
By: Arthur A. Daemmrich
Adverse drug reactions pose distinct but potentially catastrophic risks to patients, physicians, pharmaceutical firms, and regulators. Between the early 1960s and the present, national systems were built to collect, standardize, and respond to individual reports of... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Testing and Trials; Business and Government Relations; Risk and Uncertainty; Safety; Pharmaceutical Industry; United States
Daemmrich, Arthur A. "From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance." Chap. 13 in The Fragmentation of U.S. Health Care: Causes and Solutions, edited by Einer Elhauge, 301–322. Oxford: Oxford University Press, 2010.
- 23 May 2017
- First Look
First Look at New Ideas and Research: May 23, 2017
substantial variation exists across organizations with regard to management, suggesting frictions in the broader diffusion of management knowledge. We argue that peer networks may allow for the diffusion of productive management across firms. Using a View Details
Keywords: Carmen Nobel
- January 2009 (Revised July 2009)
- Case
Targanta Therapeutics: Hitting a Moving Target
By: Arthur A. Daemmrich
This case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful... View Details
Keywords: Decision Choices and Conditions; Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Business and Government Relations; Business Strategy; Biotechnology Industry; Pharmaceutical Industry
Daemmrich, Arthur A. "Targanta Therapeutics: Hitting a Moving Target." Harvard Business School Case 709-002, January 2009. (Revised July 2009.)
- 08 Apr 2009
- Research & Ideas
Clayton Christensen on Disrupting Health Care
screening participants in drug trials and make it possible to track and troubleshoot unexpected problems that show up after a drug is introduced into the general population, like what happened with Vioxx. The potential of this technology... View Details
- 02 Nov 2010
- First Look
First Look: November 2, 2010
perceived agreeableness; the decrease in leadership effectiveness perception between moderate and high decision latitude was explained by a decrease in perceived conscientiousness. Theoretical and practical implications of these findings are discussed. Keeping the... View Details
Keywords: Sean Silverthorne
- 10 Mar 2014
- Research & Ideas
Counting Up the Effects of Sarbanes-Oxley
approach when considering SOX," explains Srinivasan. The most worrisome part of the act on the business side was the mandate that required public companies to obtain an independent audit of their internal control practices. The cost... View Details